Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report

Gefitinib, the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non-small cell lung cancer (NSCLC) with common EGFR mutation. However, the efficacy of preoperative gefitinib therapy in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Wenxing, Zhao, Yandong, Xuan, Yunpeng, Qin, Yi, Xu, Rongjian, Halmos, Balazs, Fabian, Thomas, Jiao, Wenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212137/
https://www.ncbi.nlm.nih.gov/pubmed/32395295
http://dx.doi.org/10.21037/jtd.2020.02.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212137/
https://www.ncbi.nlm.nih.gov/pubmed/32395295
http://dx.doi.org/10.21037/jtd.2020.02.60

Ejemplares similares